Erlonat (Erlotinib) 150 mg
3957₴
4837₴
-18%
Erlonat 150 mg is a premium targeted therapy medication containing Erlotinib.
Manufacturer: Natco Pharma (India). Recognized globally as the "Gold Standard" generic equivalent of Tarceva.
Targeting the Driver Mutation:
Erlonat is a tyrosine kinase inhibitor (TKI) that targets the Epidermal Growth Factor Receptor (EGFR). In cancers with EGFR mutations, this receptor is stuck in the "on" position, driving tumor growth. Erlonat switches it "off".
✅ Quality: Natco's formulation is trusted by oncologists worldwide for its bioequivalence and efficacy.
Indicated for the treatment of:
- Non-Small Cell Lung Cancer (NSCLC): For patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. Also used as maintenance or second-line therapy.
- Pancreatic Cancer: Combined with Gemcitabine for locally advanced, unresectable, or metastatic disease.
Strength: 150 mg tablet.
Standard Dose: 150 mg once daily.
⚠️ CRITICAL INSTRUCTIONS:
- 🚫 Take on an EMPTY STOMACH: At least 1 hour before or 2 hours after meals. Food increases drug levels to toxic limits.
- 🚬 No Smoking: Smoking induces enzymes that metabolize the drug too fast, reducing efficacy by ~50%.
- 💊 Drug Interactions: Avoid Proton Pump Inhibitors (like Omeprazole).
- Severe hepatic impairment.
- Pregnancy (Category D) and breastfeeding.
- Active peptic ulcer disease.
- Severe hypersensitivity to Erlotinib.
Expected reactions:
- Skin Rash (Acneiform): Very common. A strong rash is often correlated with better tumor response and survival rates.
- Diarrhea: Common, usually manageable.
- Ocular changes: Dry eyes or ingrown eyelashes.
- Fatigue and loss of appetite.
100% original product
Delivery across Ukraine
Customer reviews
What Customers Say
No reviews yet
Your review can be the first!